159 related articles for article (PubMed ID: 17223541)
1. Progress and new standards of care in the management of HER-2 positive breast cancer.
Demonty G; Bernard-Marty C; Puglisi F; Mancini I; Piccart M
Eur J Cancer; 2007 Feb; 43(3):497-509. PubMed ID: 17223541
[TBL] [Abstract][Full Text] [Related]
2. [Herceptin therapy in breast cancer: new indication?].
Lebeau A
Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
[TBL] [Abstract][Full Text] [Related]
3. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
6. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
7. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
9. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
Mundy DW; Harb W; Jevremovic T
Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
11. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
12. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
[TBL] [Abstract][Full Text] [Related]
14. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
16. HER-2-targeted therapy: lessons learned and future directions.
Nahta R; Esteva FJ
Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
[TBL] [Abstract][Full Text] [Related]
17. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
18. Ongoing and planned adjuvant trials with trastuzumab.
Perez EA; Hortobagyi GN
Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer: the upgraded role of HER-3 and HER-4.
Karamouzis MV; Badra FA; Papavassiliou AG
Int J Biochem Cell Biol; 2007; 39(5):851-6. PubMed ID: 17254832
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R; Durbecq V; Di Leo A; Paesmans M; Larsimont D; Leroy JY; Borms M; Vindevoghel A; Jerusalem G; D'Hondt V; Dirix L; Canon JL; Richard V; Cocquyt V; Majois F; Reginster M; Demol J; Kains JP; Delree P; Keppens C; Sotiriou C; Piccart MJ; Cardoso F
Eur J Cancer; 2007 Mar; 43(4):725-35. PubMed ID: 17251007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]